vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-102Research ArticleДОКЛИНИЧЕСКОЕ И КЛИНИЧЕСКОЕ ИЗУЧЕНИЕ ЛЕКАРСТВЕННЫХ СРЕДСТВPRECLINICAL AND CLINICAL STUDY OF MEDICINESОпределение активности ферментов метаболизма лекарственных средств - перспектива использования в клинической практикеDetermination of the activity of drug-metabolizing enzymes - the prospects for their use in clinical practiceСмирновВ. В.SmirnovV. V.noemail@neicon.ruЕгоренковЕ. А.EgorenkovE. A.noemail@neicon.ruКрасныхЛ. М.KrasnykhL. M.noemail@neicon.ruВасиленкоГ. Ф.VasilenkoG. F.noemail@neicon.ruРаменскаяГ. В.RamenskayaG. V.noemail@neicon.ruНаучный центр экспертизы средств медицинского применения; Первый Московский государственный медицинский университет им. И. М. СеченоваРоссияScientific Centre for Expert Evaluation of Medicinal Products; I. M. Sechenov First Moscow State Medical UniversityRussian FederationПервый Московский государственный медицинский университет им. И. М. СеченоваРоссияI. M. Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation201613022018042832Copyright © Смирнов В.В., Егоренков Е.А., Красных Л.М., Василенко Г.Ф., Раменская Г.В., 20182018Смирнов В.В., Егоренков Е.А., Красных Л.М., Василенко Г.Ф., Раменская Г.В.Smirnov V.V., Egorenkov E.A., Krasnykh L.M., Vasilenko G.F., Ramenskaya G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/102

Одной из распространенных проблем современной медицины является риск возникновения нежелательных реакций при приеме различных лекарственных средств. Причины развития таких реакций могут быть разными, однако чаще всего они возникают из-за повышенной или пониженной активности системы ферментов метаболизма ксенобиотиков, в основе которой лежит система изоферментов цитохрома P450 (также известная как CYP). В настоящее время разработан ряд различных методик, позволяющих оценить активность данной системы у конкретного пациента. Авторами были изучены основные методы определения активности ферментов метаболизма лекарственных средств, подходы к их внедрению в клиническую практику и перспективы их использования с целью персонализации фармации и рационализации фармакотерапии.

One of the common issues of modern medicine is the risk of adverse drug effects when administering certain medicines. The causes of these effects may be various, but they mostly occur because of increased or decreased activity of xenobiotic-metabolizing enzymes, based on cytochrome P450 isoenzyme system (also known as CYP). For the date there is a number of different ways to determine the activity of the mentioned system in specific patient. The authors have studied the basic methods of determining the activity of drug-metabolizing enzymes and the approaches to their introduction into clinical practice, as well as the prospects of using them for the purpose of personalization of pharmacy and pharmacotherapy rationalization.

цитохром P450CYPфенотипированиеперсонализированная медицинафармакотерапияcytochrome P450CYPphenotypingpersonalized therapypharmacotherapyReferencesКукес ВГ. Метаболизм лекарственных средств: клинико-фармакологические аспекты. М.: Реафарм; 2004.Kukes VG. The metabolism of medicines: clinical and pharmacological aspects. Moscow: Reafarm; 2004 (in Russian).Кукес ВГ, Бочков НП, ред. Клиническая фармакогенетика. М.: ГЭОТАР; 2007.Kukes VG, Bochkov NP, eds. Clinical pharmacogenetics. Moscow: GEOTAR; 2007 (in Russian).Hedgecoe AM. Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Science, technology and human values 2003; 28: 513-37; Hedgecoe A. The politics of personalized medicine - pharmacogenetics in the clinic. Cambridge University Press; 2004.Hedgecoe AM. Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Science, technology and human values 2003; 28: 513–37; Hedgecoe A. The politics of personalized medicine — pharmacogenetics in the clinic. Cambridge University Press; 2004.Hocum BT, White JR, Heck JW, Thirumaran RK, Moyer N, Newman R, Ashcraft K. Cytochrome P450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016; 73(2): 61-7.Hocum BT, White JR, Heck JW, Thirumaran RK, Moyer N, Newman R, Ashcraft K. Cytochrome P450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm. 2016; 73(2): 61–7.Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17(3): 165-84.Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17(3): 165–84.Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011; 36(1): 1-16.Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011; 36(1): 1–16.Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab. 2010; 11(8): 678-85.Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab. 2010; 11(8): 678–85.Spaggiari D, Geiser L, Daali Y, Rudaz S. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal. 2014; 101: 221-37.Spaggiari D, Geiser L, Daali Y, Rudaz S. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal. 2014; 101: 221–37.Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995; 58(6): 641-9.Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995; 58(6): 641–9.Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug metabolism and disposition: the biological fate of chemicals. Drug Metab Dispos. 1995; 23(2): 207-15.Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.Drug metabolism and disposition: the biological fate of chemicals. Drug Metab Dispos. 1995; 23(2): 207–15.Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos. 1995; 23(2): 207-15.Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos. 1995; 23(2): 207–15.Choi JS, Choi I, Choi DH. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. Pharmacol Rep. 2013; 65(5): 1422-30.Choi JS, Choi I, Choi DH. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. Pharmacol Rep. 2013; 65(5): 1422–30.Zong H, Zhuge B, Lu X, Huo X, Fang H, Song J, Sun J. Characterization of a novel cytochrome P450 from Amycolatopsis sp. CGMCC1149 for hydroxylation of lovastatin. Biotechnol Appl Biochem. 2015; 62(1): 9-16.Zong H, Zhuge B, Lu X, Huo X, Fang H, Song J, Sun J. Characterization of a novel cytochrome P450 from Amycolatopsis sp. CGMCC1149 for hydroxylation of lovastatin. Biotechnol Appl Biochem. 2015; 62(1): 9–16.

The authors declare that there are no conflicts of interest present.